Cardiovascular Research

Cardiomyocyte transplantation into the failing heart-new therapeutic approach for heart failure?

Authors: Thorsten Reffelmann|||Jonathan Leor|||Jochen Müller-Ehmsen|||Larry Kedes|||Robert A Kloner

Affiliations: + Expand

Abstract

Heart failure, frequently the consequence of irreversible myocardial damage with subsequent formation of akinetic scar tissue, is a highly prevalent disease, and in its advanced stages associated with high mortality. The transplantation of exogenous cells with the inherent ability to contract has been put forward as one potential treatment strategy to increase contractility and cardiac performance. Besides skeletal myoblasts or stem cells from various sources, immature cardiomyocytes, such as fetal or neonatal cardiomyocytes, have been transplanted into normal, cryoinjured, infarcted myocardium, as well as into models of global heart failure. Survival of transplanted immature cardiomyocytes has been demonstrated up to 6-7 months, accompanied by vascularization of the grafted tissue. Transplants developed sarcomeric structures and other morphological features of differentiation. The principal possibility of cell-to-cell coupling between graft and host cells was demonstrated after cardiomyocyte transplantation into normal hearts and in some studies in damaged myocardium. But most long-term follow-up investigations in models of myocardial infarction reported that optimal integration of the engrafted cells appeared to be hindered by scar tissue, separating the transplant from the host. Nonetheless, in several studies, improved parameters of cardiac performance were demonstrated ex-vivo and in vivo. Potential mechanisms might involve beneficial effects on the remodeling process. In this review, we critically evaluate the potential value of cardiomyocyte transplantation as a new approach in the treatment of the syndrome of "heart failure".

---

Reference List

J Am Geriatr Soc. 1997 Aug;45(8):968-74|||Cell Transplant. 1998 May-Jun;7(3):239-46|||J Interv Cardiol. 1995 Aug;8(4):387-93|||Ann Thorac Surg. 1996 Sep;62(3):654-60; discussion 660-1|||Circulation. 2001 Sep 18;104(12 Suppl 1):I218-22|||Lancet. 2001 Jan 27;357(9252):279-80|||Circulation. 1999 Nov 9;100(19 Suppl):II262-8|||Curr Biol. 2001 Jun 5;11(11):855-8|||J Thorac Cardiovasc Surg. 2000 Jun;119(6):1169-75|||In Vitro Cell Dev Biol Anim. 1995 Mar;31(3):190-5|||J Intern Med. 1995 Feb;237(2):135-41|||Mech Dev. 1993 Nov;44(1):41-50|||J Cell Sci. 2000 Jan;113 ( Pt 1):5-10|||Nature. 2001 Apr 5;410(6829):701-5|||Circulation. 2002 Apr 9;105(14):1720-6|||Circ Res. 1996 Feb;78(2):283-8|||J Muscle Res Cell Motil. 1997 Feb;18(1):63-70|||Circulation. 2001 Apr 10;103(14):1920-7|||Science. 1997 Apr 4;276(5309):71-4|||N Engl J Med. 1991 Aug 1;325(5):293-302|||Circ Res. 1990 Jan;66(1):84-102|||Am Heart J. 1991 Mar;121(3 Pt 1):951-7|||N Engl J Med. 1991 Nov 21;325(21):1468-75|||Am J Pathol. 1992 Jul;141(1):183-91|||N Engl J Med. 1996 May 23;334(21):1349-55|||J Clin Invest. 1993 Sep;92(3):1115-6|||N Engl J Med. 1999 Sep 2;341(10):709-17|||Circulation. 1995 May 15;91(10):2504-7|||J Clin Invest. 1995 Oct;96(4):2034-42|||J Mol Cell Cardiol. 2002 Feb;34(2):107-16|||Ann Thorac Surg. 2001 Dec;72(6):1957-63|||Circulation. 1997 Nov 4;96(9 Suppl):II-188-93|||J Mol Cell Cardiol. 2001 May;33(5):907-21|||Ann Thorac Surg. 1999 Jan;67(1):124-9|||J Clin Invest. 1996 Dec 1;98(11):2512-23|||J Clin Invest. 1999 Mar;103(5):697-705|||J Mol Cell Cardiol. 2001 Jul;33(7):1321-30|||J Thorac Cardiovasc Surg. 1999 Oct;118(4):715-24|||Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8801-5|||Circulation. 1999 Aug 31;100(9):999-1008|||Nat Med. 1998 Aug;4(8):929-33|||J Am Coll Cardiol. 1992 Jul;20(1):248-54|||Circ Res. 1996 Apr;78(4):547-52|||Arch Mal Coeur Vaiss. 2001 Mar;94(3):180-2|||Eur Heart J. 1983 Jul;4(7):445-8|||N Engl J Med. 2001 Jun 7;344(23):1750-7|||Science. 1999 Apr 2;284(5411):143-7|||J Clin Invest. 1995 Jan;95(1):114-21|||J Mol Cell Cardiol. 1996 Oct;28(10):2057-67|||Circulation. 1996 Nov 1;94(9 Suppl):II337-40|||Circulation. 2000 Nov 7;102(19 Suppl 3):III359-64|||Circulation. 1996 Nov 1;94(9 Suppl):II332-6|||FASEB J. 2000 Dec;14(15):2540-8|||Proc Assoc Am Physicians. 1997 May;109(3):245-53|||Circ Res. 1999 Aug 6;85(3):294-301|||Dtsch Med Wochenschr. 2001 Aug 24;126(34-35):932-8|||Pediatr Res. 1988 Jun;23(6):637-42|||Circulation. 2000 Nov 7;102(19 Suppl 3):III204-9|||Circulation. 1996 Sep 15;94(6):1394-401|||Circulation. 1999 Nov 9;100(19 Suppl):II247-56|||Circulation. 1998 Nov 10;98(19 Suppl):II151-5; discussion II155-6|||Circulation. 1997 Nov 4;96(9 Suppl):II-179-86; discussion 186-7|||Transplant Proc. 1997 Jun;29(4):2093-4|||J Mol Cell Cardiol. 1996 Aug;28(8):1737-46|||Circulation. 1999 Jul 13;100(2):193-202|||Am J Physiol. 1993 May;264(5 Pt 2):H1727-33|||World J Surg. 2000 Jul;24(7):811-4|||Dev Biol. 1994 Mar;162(1):9-17|||Science. 1994 Apr 1;264(5155):98-101